Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening

Abstract

Background Several vaccines are now clinically available under emergency use authorization in the United States and have demonstrated efficacy against symptomatic COVID-19. The impact of vaccines on asymptomatic SARS-CoV-2 infection is largely unknown. Methods We conducted a retrospective cohort study of consecutive, asymptomatic adult patients (n = 39,156) within a large United States healthcare system who underwent 48,333 pre-procedural SARS-CoV-2 molecular screening tests between December 17, 2020 and February 8, 2021. The primary exposure of interest was vaccination with at least one dose of an mRNA COVID-19 vaccine. The primary outcome was relative risk of a positive SARS-CoV-2 molecular test among those asymptomatic persons who had received at least one dose of vaccine, as compared to persons who had not received vaccine during the same time period. Relative risk was adjusted for age, sex, race/ethnicity, patient residence relative to the hospital (local vs. non-local), healthcare system regions, and repeated screenings among patients using mixed effects log-binomial regression. Results Positive molecular tests in asymptomatic individuals were reported in 42 (1.4%) of 3,006 tests performed on vaccinated patients and 1,436 (3.2%) of 45,327 tests performed on unvaccinated patients (RR=0.44 95% CI: 0.33-0.60; p<.0001). Compared to unvaccinated patients, the risk of asymptomatic SARS-CoV-2 infection was lower among those >10 days after 1 st dose (RR=0.21; 95% CI: 0.12-0.37; p<.0001) and >0 days after 2 nd dose (RR=0.20; 95% CI: 0.09-0.44; p<.0001) in the adjusted analysis. Conclusions COVID-19 vaccination with an mRNA-based vaccine showed a significant association with a reduced risk of asymptomatic SARS-CoV-2 infection as measured during pre-procedural molecular screening. The results of this study demonstrate the impact of the vaccines on reduction in asymptomatic infections supplementing the randomized trial results on symptomatic patients.

Outbreak of SARS-CoV-2 Lineage 20I/501Y.V1 in a Nursing Home Underlines the Crucial Role of Vaccination in Both Residents and Staff

“…This also makes it difficult to compare estimates coming from different areas. A recent retrospective cohort study by Tande et al [29] has established a vaccine effectiveness of 80% (95% CI: 56-91%) against asymptomatic SARS-CoV-2 infection after two doses of the mRNA vaccines. An observational study from Israel [20] reported a higher estimate: in the period of ≥7 days after the second dose of BNT162b2 the vaccine effectiveness in the elderly was 88.5% (95% CI: 86.4-90.3%).…”

Brief review of the mRNA vaccines COVID-19

“…Certainly, the decrease in the number of people with severe COVID-19 infection, mediated by vaccination, will also decrease the duration time of transmission and contagiousness, indirectly reducing also the contagion between men. In addition, evidence shows also a reduction in the number of asymptomatic cases in vaccinated individuals (Tande et al 2021). Moreover, new variants of SARS-CoV-2 have recently been identified in the United Kingdom and South Africa (Conti et al 2021;Giovanetti et al 2021).…”

Modeling the impact of COVID-19 vaccination in Lebanon: A call to speed-up vaccine roll out

“…With over one million refugees on its territory, Lebanon also hosts the highest per capita number of refugees worldwide [3], a population highly vulnerable to large SARS-CoV-2 outbreaks [4]. At this stage, mass vaccination with the recently available and highly efficacious COVID-19 vaccines [5][6][7][8][9] brings hope to control infection spread and mitigate its profound impact, especially with the emerging 'real-world' evidence of their high effectiveness in reducing both symptomatic and asymptomatic disease [10][11][12][13].…”